 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Isomerase/DNA
|
PDB id
|
|
|
|
1seu
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.5.99.1.2
- Dna topoisomerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP-independent breakage of single-stranded DNA, followed by passage and rejoining.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
chromosome
|
1 term
|
 |
|
Biological process
|
DNA topological change
|
2 terms
|
 |
|
Biochemical function
|
DNA binding
|
3 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
48:2336-2345
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
|
|
B.L.Staker,
M.D.Feese,
M.Cushman,
Y.Pommier,
D.Zembower,
L.Stewart,
A.B.Burgin.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human topoisomerase I (top1) is the molecular target of a diverse set of
anticancer compounds, including the camptothecins, indolocarbazoles, and
indenoisoquinolines. These compounds bind to a transient top1-DNA covalent
complex and inhibit the resealing of a single-strand nick that the enzyme
creates to relieve superhelical tension in duplex DNA. (Hertzberg, R. P.; et al.
Biochem. 1989, 28, 4629-4638. Hsiang, Y. H.; et al. J. Biol. Chem 1985, 260,
14873-14878. Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369-413. Stewart, L.;
et al. Science 1998, 729, 1534-1541.) We report the X-ray crystal structures of
the human top1-DNA complex bound with camptothecin and representative members of
the indenoisoquinoline and indolocarbazole classes of top1 poisons. The planar
nature of all three structurally diverse classes allows them to intercalate
between DNA base pairs at the site of single-strand cleavage. All three classes
of compounds have a free electron pair near Arg364, a residue that if mutated
confers resistance to all three classes of drugs. The common intercalative
binding mode is augmented by unexpected chemotype-specific contacts with amino
acid residues Asn352 and Glu356, which adopt alternative side-chain
conformations to accommodate the bound compounds. These new X-ray structures
explain how very different molecules can stabilize top1-DNA covalent complexes
and will aid the rational design of completely novel structural classes of
anticancer drugs.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
W.Liu,
L.Zhu,
W.Guo,
C.Zhuang,
Y.Zhang,
C.Sheng,
P.Cheng,
J.Yao,
W.Wang,
G.Dong,
S.Wang,
Z.Miao,
and
W.Zhang
(2011).
Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
|
| |
Eur J Med Chem, 46,
2408-2414.
|
 |
|
|
|
|
 |
B.A.Neto,
A.A.Lapis,
F.S.Mancilha,
E.L.Batista,
P.A.Netz,
F.Rominger,
L.A.Basso,
D.S.Santos,
and
J.Dupont
(2010).
On the selective detection of duplex deoxyribonucleic acids by 2,1,3-benzothiadiazole fluorophores.
|
| |
Mol Biosyst, 6,
967-975.
|
 |
|
|
|
|
 |
C.Samorì,
G.L.Beretta,
G.Varchi,
A.Guerrini,
S.Di Micco,
S.Basili,
G.Bifulco,
R.Riccio,
S.Moro,
E.Bombardelli,
F.Zunino,
and
G.Fontana
(2010).
Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach.
|
| |
ChemMedChem, 5,
2006-2015.
|
 |
|
|
|
|
 |
M.R.Stahley,
and
J.T.Stivers
(2010).
Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.
|
| |
Biochemistry, 49,
2786-2795.
|
 |
|
|
|
|
 |
O.Y.Susova,
A.A.Ivanov,
S.S.Morales Ruiz,
E.A.Lesovaya,
A.V.Gromyko,
S.A.Streltsov,
and
A.L.Zhuze
(2010).
Minor groove dimeric bisbenzimidazoles inhibit in vitro DNA binding to eukaryotic DNA topoisomerase I.
|
| |
Biochemistry (Mosc), 75,
695-701.
|
 |
|
|
|
|
 |
T.Cheng,
Y.Wang,
and
S.H.Bryant
(2010).
Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules.
|
| |
Bioinformatics, 26,
2881-2888.
|
 |
|
|
|
|
 |
Y.Song,
Z.Shao,
T.S.Dexheimer,
E.S.Scher,
Y.Pommier,
and
M.Cushman
(2010).
Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.
|
| |
J Med Chem, 53,
1979-1989.
|
 |
|
|
|
|
 |
B.B.Das,
S.Antony,
S.Gupta,
T.S.Dexheimer,
C.E.Redon,
S.Garfield,
Y.Shiloh,
and
Y.Pommier
(2009).
Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK.
|
| |
EMBO J, 28,
3667-3680.
|
 |
|
|
|
|
 |
H.T.Chiu,
Y.C.Lin,
M.N.Lee,
Y.L.Chen,
M.S.Wang,
and
C.C.Lai
(2009).
Biochemical characterization and substrate specificity of the gene cluster for biosyntheses of K-252a and its analogs by in vitro heterologous expression system of Escherichia coli.
|
| |
Mol Biosyst, 5,
1192-1203.
|
 |
|
|
|
|
 |
K.G.Byler,
C.Wang,
and
W.N.Setzer
(2009).
Quinoline alkaloids as intercalative topoisomerase inhibitors.
|
| |
J Mol Model, 15,
1417-1426.
|
 |
|
|
|
|
 |
M.A.Cinelli,
B.Cordero,
T.S.Dexheimer,
Y.Pommier,
and
M.Cushman
(2009).
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.
|
| |
Bioorg Med Chem, 17,
7145-7155.
|
 |
|
|
|
|
 |
N.M.Baker,
R.Rajan,
and
A.Mondragón
(2009).
Structural studies of type I topoisomerases.
|
| |
Nucleic Acids Res, 37,
693-701.
|
 |
|
|
|
|
 |
R.P.Bakshi,
D.Sang,
A.Morrell,
M.Cushman,
and
T.A.Shapiro
(2009).
Activity of indenoisoquinolines against African trypanosomes.
|
| |
Antimicrob Agents Chemother, 53,
123-128.
|
 |
|
|
|
|
 |
Y.Pommier,
and
M.Cushman
(2009).
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
|
| |
Mol Cancer Ther, 8,
1008-1014.
|
 |
|
|
|
|
 |
Y.Pommier
(2009).
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
|
| |
Chem Rev, 109,
2894-2902.
|
 |
|
|
|
|
 |
Z.F.Chen,
Y.C.Liu,
L.M.Liu,
H.S.Wang,
S.H.Qin,
B.L.Wang,
H.D.Bian,
B.Yang,
H.K.Fun,
H.G.Liu,
H.Liang,
and
C.Orvig
(2009).
Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies.
|
| |
Dalton Trans, 0,
262-272.
|
 |
|
|
|
|
 |
F.Animati,
M.Berettoni,
M.Bigioni,
M.Binaschi,
P.Felicetti,
L.Gontrani,
O.Incani,
A.Madami,
E.Monteagudo,
L.Olivieri,
S.Resta,
C.Rossi,
and
A.Cipollone
(2008).
Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.
|
| |
ChemMedChem, 3,
266-279.
|
 |
|
|
|
|
 |
G.Chillemi,
I.D'Annessa,
P.Fiorani,
C.Losasso,
P.Benedetti,
and
A.Desideri
(2008).
Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.
|
| |
Nucleic Acids Res, 36,
5645-5651.
|
 |
|
|
|
|
 |
J.E.Deweese,
A.B.Burgin,
and
N.Osheroff
(2008).
Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.
|
| |
Biochemistry, 47,
4129-4140.
|
 |
|
|
|
|
 |
M.A.Cinelli,
A.Morrell,
T.S.Dexheimer,
E.S.Scher,
Y.Pommier,
and
M.Cushman
(2008).
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.
|
| |
J Med Chem, 51,
4609-4619.
|
 |
|
|
|
|
 |
M.Christmann,
M.T.Tomicic,
C.Gestrich,
W.P.Roos,
V.A.Bohr,
and
B.Kaina
(2008).
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
|
| |
DNA Repair (Amst), 7,
1999-2009.
|
 |
|
|
|
|
 |
M.van der Merwe,
and
M.A.Bjornsti
(2008).
Mutation of gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
|
| |
J Biol Chem, 283,
3305-3315.
|
 |
|
|
|
|
 |
T.S.Dexheimer,
and
Y.Pommier
(2008).
DNA cleavage assay for the identification of topoisomerase I inhibitors.
|
| |
Nat Protoc, 3,
1736-1750.
|
 |
|
|
|
|
 |
X.Chen,
S.Zhong,
X.Zhu,
B.Dziegielewska,
T.Ellenberger,
G.M.Wilson,
A.D.MacKerell,
and
A.E.Tomkinson
(2008).
Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair.
|
| |
Cancer Res, 68,
3169-3177.
|
 |
|
|
|
|
 |
Y.Song,
and
M.Cushman
(2008).
The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.
|
| |
J Phys Chem B, 112,
9484-9489.
|
 |
|
|
|
|
 |
A.Lauria,
M.Ippolito,
and
A.M.Almerico
(2007).
Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.
|
| |
J Mol Model, 13,
393-400.
|
 |
|
|
|
|
 |
A.Morrell,
M.S.Placzek,
J.D.Steffen,
S.Antony,
K.Agama,
Y.Pommier,
and
M.Cushman
(2007).
Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
|
| |
J Med Chem, 50,
2040-2048.
|
 |
|
|
|
|
 |
C.Hansch,
and
R.P.Verma
(2007).
20-(S)-Camptothecin Analogues as DNA Topoisomerase I Inhibitors: A QSAR Study.
|
| |
ChemMedChem, 2,
1807-1813.
|
 |
|
|
|
|
 |
C.Punchihewa,
J.Dai,
M.Carver,
and
D.Yang
(2007).
Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a molten globule: implication for the formation of competent productive complex.
|
| |
J Struct Biol, 159,
111-121.
|
 |
|
|
|
|
 |
I.Choi,
C.Kim,
and
S.Choi
(2007).
Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA.
|
| |
Arch Pharm Res, 30,
1526-1535.
|
 |
|
|
|
|
 |
K.S.Ryan,
A.R.Howard-Jones,
M.J.Hamill,
S.J.Elliott,
C.T.Walsh,
and
C.L.Drennan
(2007).
Crystallographic trapping in the rebeccamycin biosynthetic enzyme RebC.
|
| |
Proc Natl Acad Sci U S A, 104,
15311-15316.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.A.Khan,
and
D.S.Pilch
(2007).
Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site.
|
| |
J Mol Biol, 365,
561-569.
|
 |
|
|
|
|
 |
R.F.Frøhlich,
C.Veigaard,
F.F.Andersen,
A.K.McClendon,
A.C.Gentry,
A.H.Andersen,
N.Osheroff,
T.Stevnsner,
and
B.R.Knudsen
(2007).
Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal.
|
| |
Nucleic Acids Res, 35,
6170-6180.
|
 |
|
|
|
|
 |
Y.Zu,
C.Gao,
W.Wang,
F.Yang,
Y.Liu,
M.Wang,
and
Y.Zhao
(2007).
Characteristics of the microbial community in rhizosphere of Camptotheca acuminata cultured with exotic invasive plant Eupatorium adenophorum.
|
| |
Sci China C Life Sci, 50,
22-30.
|
 |
|
|
|
|
 |
A.Morrell,
S.Antony,
G.Kohlhagen,
Y.Pommier,
and
M.Cushman
(2006).
A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
|
| |
J Med Chem, 49,
7740-7753.
|
 |
|
|
|
|
 |
A.Patel,
S.Shuman,
and
A.Mondragón
(2006).
Crystal structure of a bacterial type IB DNA topoisomerase reveals a preassembled active site in the absence of DNA.
|
| |
J Biol Chem, 281,
6030-6037.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Marchand,
S.Antony,
K.W.Kohn,
M.Cushman,
A.Ioanoviciu,
B.L.Staker,
A.B.Burgin,
L.Stewart,
and
Y.Pommier
(2006).
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
|
| |
Mol Cancer Ther, 5,
287-295.
|
 |
|
|
|
|
 |
C.Sánchez,
C.Méndez,
and
J.A.Salas
(2006).
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity.
|
| |
Nat Prod Rep, 23,
1007-1045.
|
 |
|
|
|
|
 |
H.Takemura,
V.A.Rao,
O.Sordet,
T.Furuta,
Z.H.Miao,
L.Meng,
H.Zhang,
and
Y.Pommier
(2006).
Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.
|
| |
J Biol Chem, 281,
30814-30823.
|
 |
|
|
|
|
 |
K.Perry,
Y.Hwang,
F.D.Bushman,
and
G.D.Van Duyne
(2006).
Structural basis for specificity in the poxvirus topoisomerase.
|
| |
Mol Cell, 23,
343-354.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Nagarajan,
A.Morrell,
A.Ioanoviciu,
S.Antony,
G.Kohlhagen,
K.Agama,
M.Hollingshead,
Y.Pommier,
and
M.Cushman
(2006).
Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.
|
| |
J Med Chem, 49,
6283-6289.
|
 |
|
|
|
|
 |
P.Fiorani,
G.Chillemi,
C.Losasso,
S.Castelli,
and
A.Desideri
(2006).
The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.
|
| |
Nucleic Acids Res, 34,
5093-5100.
|
 |
|
|
|
|
 |
R.Balaña-Fouce,
C.M.Redondo,
Y.Pérez-Pertejo,
R.Díaz-González,
and
R.M.Reguera
(2006).
Targeting atypical trypanosomatid DNA topoisomerase I.
|
| |
Drug Discov Today, 11,
733-740.
|
 |
|
|
|
|
 |
X.Xiao,
S.Antony,
Y.Pommier,
and
M.Cushman
(2006).
Total synthesis and biological evaluation of 22-hydroxyacuminatine.
|
| |
J Med Chem, 49,
1408-1412.
|
 |
|
|
|
|
 |
Y.Pommier
(2006).
Topoisomerase I inhibitors: camptothecins and beyond.
|
| |
Nat Rev Cancer, 6,
789-802.
|
 |
|
|
|
|
 |
Y.Pommier,
J.M.Barcelo,
V.A.Rao,
O.Sordet,
A.G.Jobson,
L.Thibaut,
Z.H.Miao,
J.A.Seiler,
H.Zhang,
C.Marchand,
K.Agama,
J.L.Nitiss,
and
C.Redon
(2006).
Repair of topoisomerase I-mediated DNA damage.
|
| |
Prog Nucleic Acid Res Mol Biol, 81,
179-229.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|